Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 févr. 2022 07h12 HE | Source: Resverlogix Corp

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...
12 oct. 2021 16h35 HE | Source: Resverlogix Corp

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the...
13 sept. 2021 08h00 HE | Source: Resverlogix Corp

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a...